论文部分内容阅读
目的分析抗癫痫药物(AEDs)临床疗效与血药浓度之间的关系,为临床合理用药提供个体化用药参考,探讨如何开展抗癫痫类药血药浓度监测后的药学服务。方法采用酶扩增均相免疫分析法(EMIT)监测抗癫痫类药物丙戊酸钠(VPA)、苯妥英钠(PHT)、卡马西平(CBZ)血药浓度,回顾性调查、统计分析2009-2011年945例次VPA、278例次PHT、157例次CBZ血药浓度监测结果。结果其中55.3%的患者VPA监测结果在有效参考血药浓度范围以内,31.7%的患者PHT监测结果在有效血药浓度范围以内,79.0%的患者CBZ监测结果在有效参考血药浓度范围内。结论抗癫痫药物血药浓度监测是临床用药的依据之一,临床药师于血药浓度监测后为患者提供个体化给药建议,对合理用药有重要的指导意义。
Objective To analyze the relationship between clinical efficacy and plasma concentration of antiepileptic drugs (AEDs), provide personalized reference for clinical rational drug use, and explore how to carry out pharmacy services after antiepileptic drug serum concentration monitoring. Methods The plasma concentrations of antiepileptic drugs VPA, PHT and CBZ were monitored by enzyme-linked immunosorbent assay (UPLC). Retrospective investigation, 945 cases of VPA in 2011, 278 cases of PHT, 157 cases of CBZ blood concentration monitoring results. Results 55.3% of patients VPA monitoring results within the effective reference blood concentration range, 31.7% of the patients PHT monitoring results within the effective blood concentration range, 79.0% of the patients CBZ monitoring results within the effective reference blood concentration range. Conclusion The monitoring of serum concentration of anti-epileptic drugs is one of the bases of clinical medication. Clinical pharmacists provide personalized advice to patients after blood drug concentration monitoring, which has important guiding significance for rational drug use.